vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and CuriosityStream Inc. (CURI). Click either name above to swap in a different company.
CuriosityStream Inc. is the larger business by last-quarter revenue ($19.2M vs $18.7M, roughly 1.0× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -19.7%, a 18.9% gap on every dollar of revenue. On growth, CuriosityStream Inc. posted the faster year-over-year revenue change (35.8% vs -25.7%). CuriosityStream Inc. produced more free cash flow last quarter ($3.9M vs $-15.8M). Over the past eight quarters, CuriosityStream Inc.'s revenue compounded faster (26.5% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Curiosity Stream Inc., formerly branded as CuriosityStream, is an American media company and over-the-top subscription video streaming service which offers documentary programming including films, series, and TV shows. The company offers a video on demand subscription service branded as "Curiosity Stream" and a linear broadcast television channel known as the Curiosity Channel through various services including FuboTV and The Roku Channel.
CTMX vs CURI — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $19.2M |
| Net Profit | $-154.0K | $-3.8M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | -17.6% |
| Net Margin | -0.8% | -19.7% |
| Revenue YoY | -25.7% | 35.8% |
| Net Profit YoY | 97.6% | -34.6% |
| EPS (diluted) | — | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $19.2M | ||
| Q3 25 | — | $18.4M | ||
| Q2 25 | $18.7M | $19.0M | ||
| Q1 25 | $50.9M | $15.1M | ||
| Q4 24 | $38.1M | $14.1M | ||
| Q3 24 | $33.4M | $12.6M | ||
| Q2 24 | $25.1M | $12.4M | ||
| Q1 24 | $41.5M | $12.0M |
| Q4 25 | — | $-3.8M | ||
| Q3 25 | — | $-3.7M | ||
| Q2 25 | $-154.0K | $784.0K | ||
| Q1 25 | $23.5M | $319.0K | ||
| Q4 24 | $18.9M | $-2.8M | ||
| Q3 24 | $5.7M | $-3.1M | ||
| Q2 24 | $-6.5M | $-2.0M | ||
| Q1 24 | $13.8M | $-5.0M |
| Q4 25 | — | -17.6% | ||
| Q3 25 | — | -24.5% | ||
| Q2 25 | -6.9% | 2.5% | ||
| Q1 25 | 44.4% | 0.5% | ||
| Q4 24 | 46.4% | -27.4% | ||
| Q3 24 | 12.3% | -25.8% | ||
| Q2 24 | -33.7% | -20.6% | ||
| Q1 24 | 28.1% | -30.4% |
| Q4 25 | — | -19.7% | ||
| Q3 25 | — | -20.4% | ||
| Q2 25 | -0.8% | 4.1% | ||
| Q1 25 | 46.2% | 2.1% | ||
| Q4 24 | 49.6% | -19.9% | ||
| Q3 24 | 17.2% | -24.3% | ||
| Q2 24 | -26.0% | -16.4% | ||
| Q1 24 | 33.3% | -42.0% |
| Q4 25 | — | $-0.07 | ||
| Q3 25 | — | $-0.06 | ||
| Q2 25 | — | $0.01 | ||
| Q1 25 | — | $0.01 | ||
| Q4 24 | — | $-0.05 | ||
| Q3 24 | — | $-0.06 | ||
| Q2 24 | — | $-0.04 | ||
| Q1 24 | — | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $27.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $41.5M |
| Total Assets | $175.1M | $75.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $27.3M | ||
| Q3 25 | — | $27.8M | ||
| Q2 25 | $49.0M | $28.1M | ||
| Q1 25 | $47.6M | $33.4M | ||
| Q4 24 | $38.1M | $32.1M | ||
| Q3 24 | $40.6M | $33.2M | ||
| Q2 24 | $43.2M | $39.5M | ||
| Q1 24 | $36.2M | $38.8M |
| Q4 25 | — | $41.5M | ||
| Q3 25 | — | $47.2M | ||
| Q2 25 | $119.9M | $49.8M | ||
| Q1 25 | $25.0M | $58.1M | ||
| Q4 24 | $-456.0K | $57.8M | ||
| Q3 24 | $-23.5M | $62.2M | ||
| Q2 24 | $-31.2M | $64.8M | ||
| Q1 24 | $-31.7M | $67.0M |
| Q4 25 | — | $75.7M | ||
| Q3 25 | — | $74.7M | ||
| Q2 25 | $175.1M | $78.7M | ||
| Q1 25 | $98.5M | $85.3M | ||
| Q4 24 | $120.5M | $86.2M | ||
| Q3 24 | $139.0M | $87.6M | ||
| Q2 24 | $159.2M | $90.9M | ||
| Q1 24 | $184.7M | $94.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $4.0M |
| Free Cash FlowOCF − Capex | $-15.8M | $3.9M |
| FCF MarginFCF / Revenue | -84.6% | 20.5% |
| Capex IntensityCapex / Revenue | 0.1% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $4.0M | ||
| Q3 25 | — | $4.4M | ||
| Q2 25 | $-15.8M | $2.8M | ||
| Q1 25 | $-21.0M | $1.9M | ||
| Q4 24 | $-19.9M | $3.0M | ||
| Q3 24 | $-20.7M | $2.3M | ||
| Q2 24 | $-19.5M | $2.2M | ||
| Q1 24 | $-26.0M | $666.0K |
| Q4 25 | — | $3.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | $1.8M | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — |
| Q4 25 | — | 20.5% | ||
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | 12.2% | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — |
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | 0.1% | 0.0% | ||
| Q1 25 | 0.2% | 0.5% | ||
| Q4 24 | 0.2% | 0.0% | ||
| Q3 24 | 0.1% | 0.0% | ||
| Q2 24 | 0.4% | 0.0% | ||
| Q1 24 | 0.3% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 3.56× | ||
| Q1 25 | -0.89× | 6.03× | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
CURI
Segment breakdown not available.
